| P50 | author | Mariusz L Hartman | Q59660628 |
| | Malgorzata Sztiller-Sikorska | Q91587525 |
| | Malgorzata Czyz | Q37836897 |
| P2093 | author name string | Anna Gajos-Michniewicz | |
| P2860 | cites work | Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction | Q24315032 |
| | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 |
| | Resistant mechanisms to BRAF inhibitors in melanoma | Q26739717 |
| | MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 |
| | Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. | Q27851698 |
| | Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines | Q27852814 |
| | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma | Q27852990 |
| | Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 |
| | Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance | Q27853210 |
| | Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 |
| | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 |
| | The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. | Q30837718 |
| | An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition | Q33769541 |
| | Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. | Q34032640 |
| | A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors | Q34132936 |
| | Targeting the EGFR signaling pathway in cancer therapy | Q34246558 |
| | SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. | Q34269756 |
| | Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma | Q34664981 |
| | Genomic Classification of Cutaneous Melanoma | Q34670776 |
| | Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas | Q35018167 |
| | Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells | Q35111429 |
| | Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype | Q35147858 |
| | Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment | Q35384598 |
| | Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state | Q35487251 |
| | Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma | Q35596369 |
| | MITF Modulates Therapeutic Resistance through EGFR Signaling | Q35738447 |
| | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response | Q35791205 |
| | Detection of p75NTR Trimers: Implications for Receptor Stoichiometry and Activation. | Q35995960 |
| | Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms | Q36338753 |
| | EGFR in melanoma: clinical significance and potential therapeutic target | Q39586032 |
| | MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. | Q39630026 |
| | Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. | Q40056945 |
| | Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro | Q41501598 |
| | Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response | Q42038580 |
| | Ligand-independent signaling by disulfide-crosslinked dimers of the p75 neurotrophin receptor | Q42543970 |
| | Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance | Q45347095 |
| | Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E. | Q46132721 |
| | Serum epidermal growth factor receptor levels in patients with malignant melanoma | Q46840133 |
| | low neurotrophin receptor CD271 regulates phenotype switching in melanoma | Q47103221 |
| | Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development. | Q48090844 |
| | Inducibly decreased MITF levels do not affect proliferation and phenotype switching but reduce differentiation of melanoma cells. | Q48167225 |
| | Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. | Q48243258 |
| | Microenvironment‑driven resistance to B‑Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts | Q49379553 |
| | Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells. | Q50962170 |
| | Sox2 is dispensable for primary melanoma and metastasis formation. | Q51075741 |
| | Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo. | Q51075761 |
| | Phenotypic diversity of patient-derived melanoma populations in stem cell medium. | Q51641309 |
| | Cutaneous melanoma: From pathogenesis to therapy (Review). | Q52658584 |
| | Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. | Q52719267 |
| | Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer. | Q53177105 |
| | SOX9 regulates ERBB signalling in pancreatic cancer development. | Q53229089 |
| | AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. | Q53701225 |
| | BRAF and MEK inhibitor therapy eliminates nestin expressing melanoma cells in human tumors. | Q54978739 |
| | Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance. | Q55424318 |
| | Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor). | Q55492453 |
| | Toward Minimal Residual Disease-Directed Therapy in Melanoma | Q57188242 |
| | CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma | Q57293755 |
| | Erratum: A stress-induced early innate response causes multidrug tolerance in melanoma | Q57636610 |
| | Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma | Q58024450 |
| | Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma | Q58586593 |
| | Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment | Q60521038 |
| | HGF/c-MET Signaling in Melanocytes and Melanoma | Q60920855 |
| | EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells | Q61807553 |
| | Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma | Q64064520 |
| | A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors | Q64083396 |
| | Role of miRNAs in Melanoma Metastasis | Q64119763 |
| | IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor | Q72901004 |
| | SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma | Q89112339 |
| | Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies | Q89312213 |
| | The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway | Q89405810 |
| | Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities | Q90424217 |
| | Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells | Q90579327 |
| | The great escape: tumour cell plasticity in resistance to targeted therapy | Q90641451 |
| | ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma | Q90706191 |
| | RBMX family proteins connect the fields of nuclear RNA processing, disease and sex chromosome biology | Q90800009 |
| | Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma | Q91450739 |
| | Many ways to resistance: How melanoma cells evade targeted therapies | Q91678258 |
| | Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway | Q91725276 |
| | S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells | Q92081486 |
| | The current state of molecular testing in the treatment of patients with solid tumors, 2019 | Q92214210 |
| | Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program | Q92240577 |
| | Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy | Q92344290 |
| | Fibroblast Growth Factor Receptor Signaling in Skin Cancers | Q92544513 |
| | Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma | Q92642778 |
| | Phenotype plasticity as enabler of melanoma progression and therapy resistance | Q92826006 |
| | Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro | Q92960597 |
| | 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes | Q93118409 |
| | Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance | Q36489360 |
| | Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma | Q36507554 |
| | Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells | Q36605057 |
| | Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy | Q36698266 |
| | Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib | Q36882715 |
| | Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor | Q36929804 |
| | Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas | Q37118264 |
| | Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma | Q37239090 |
| | TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma | Q37401151 |
| | Epidermal growth factor regulates the expression of its own receptor | Q37538959 |
| | Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. | Q37570262 |
| | Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy | Q37606223 |
| | The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma | Q37626102 |
| | MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition | Q37626175 |
| | Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma | Q37641646 |
| | Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma | Q37660341 |
| | Precision medicine driven by cancer systems biology | Q37742635 |
| | Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma | Q38238524 |
| | Pro-survival role of MITF in melanoma | Q38241749 |
| | The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma | Q38559739 |
| | A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib | Q38757495 |
| | Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. | Q38849622 |
| | Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway | Q38995370 |
| | BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. | Q39030603 |
| | MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. | Q39120374 |
| | Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. | Q39375855 |
| | SOX2 contributes to melanoma cell invasion | Q39425345 |
| | Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation | Q39583072 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotypic plasticity | Q295130 |
| P304 | page(s) | 142 | |
| P577 | publication date | 2020-01-07 | |
| P1433 | published in | Cells | Q27724621 |
| P1476 | title | Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity | |
| P478 | volume | 9 | |